ArticleInternational journal of reproductive biomedicine2026
Comparative study of niosomal nanoparticles encapsulating
Article in International journal of reproductive biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the second leading cause of cancer-related deaths among women, accounting for approximately 30% of all new cancer diagnoses in women annually. Objective: Given the prevalence of breast cancer among women, the primary objective of this study was to develop an effective drug delivery system for treating this disease using niosome containing Materials and Methods: This in vitro study involved the hydroalcoholic extraction of Artemisia using both the Maceration and Soxhlet methods, followed by the evaluation of its antioxidant properties. Niosomal nanoparticles were synthesized via the thin-film hydration technique. Characterization of the nanoparticles, including particle size and zeta potential, was conducted using dynamic light scattering (Zeta Sizer) and Fourier-transform infrared spectroscopy. Cytotoxicity assessment was performed employing the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, with statistical analysis carried out using one-way ANOVA and determination of significance. Results: This study demonstrated that Conclusion: Based on the results, the use of plant extracts and niosomal nanoparticles can be considered a positive step for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.